Daiichi Sankyo Company, Limited DSNKY
17.97 USD +0.07 (+0.39%)
At closeNov 13, 2026, 4:00 PM EST
17.90 Day range 17.99
15.10 52-week range 24.75
- YTD
- -15.40%
- 1 year
- -17.30%
- Market cap
- 32.74B
- EPS (ttm)
- 0.98
- P/E ratio
- 18.34
- YTD return
- -15.40%
- 1-year return
- -17.30%
- Volume
- 5.82K
- Avg volume
- 148.11K
- Open
- 17.91
- Previous close
- 17.90
- Day's range
- 17.90 – 17.99
- 52-week range
- 15.10 – 24.75
- Earnings date
- Oct 30, 2026
5D -0.60 (-3.28%)
Next earnings
Oct 30, 2026
Expected Oct 30, 2026. Consensus EPS estimate 0.2362.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2026 | Sep 30, 2026 | 0.2362 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.2543 | 0.24 | -0.01 | -5.62% |
| May 11, 2026 | Mar 31, 2026 | 0.3317 | 0.1465 | -0.19 | -55.83% |
| Jan 29, 2026 | Dec 31, 2025 | 0.2504 | 0.3033 | +0.05 | +21.13% |
| Oct 31, 2025 | Sep 30, 2025 | 0.2986 | 0.1592 | -0.14 | -46.68% |
| Jul 31, 2025 | Jun 30, 2025 | 0.2337 | 0.3059 | +0.07 | +30.89% |
News
Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study
Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Friday
Stocks That Managed to Breach 52-Week Highs Wednesday Morning
Your note
Sign in to keep a note on DSNKY — it syncs with the Stock Master app.
